Literature DB >> 23809995

Effects of montelukast on the healing of ischemic colon anastomoses.

Atilla Celik1, Ersin Ergun, Neset Koksal, Aysun Simsek Celik, Ediz Altinli, Mehmet Ali Uzun, Ersan Eroglu, Ahu Kemik.   

Abstract

BACKGROUND: The aim of this study was to examine whether treatment with montelukast, a selective leukotriene antagonist, would affect anastomotic healing in a reperfused colon rat model with remote ischemia/reperfusion injury.
METHODS: Rats (n = 12 per group) were intraperitoneally administered normal saline or 10 mg/kg montelukast sodium 60 minutes before and for 5 days after surgery. Ischemia was induced for 45 minutes through superior mesenteric artery occlusion. A left colon anastomosis was made. Blood and perianastomotic tissue samples were obtained on postoperative day 5.
RESULTS: Mean anastomotic bursting pressures of the control and montelukast groups were 159.17 ± 29.99 and 216.67 ± 26.40, respectively (P < .001). Compared with saline, montelukast treatment increased the mean tissue hydroxyproline level (2.46 ± .30 vs 3.61 ± .33 μmol/L) and decreased tissue caspase-3 activity (36.06 ± 5.72 vs 21.78 ± 3.87) and malondialdehyde levels (3.43 ± .34 vs 2.29 ± .34 nmol/g) (P < .001 for all). Other plasma markers of injury also showed differences.
CONCLUSIONS: Montelukast prevented ischemia/reperfusion-induced damage in a rat model of colonic anastomotic wound healing.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colon anastomoses; Ischemia/reperfusion; Montelukast

Mesh:

Substances:

Year:  2013        PMID: 23809995     DOI: 10.1016/j.amjsurg.2013.03.003

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Therapeutic improvement of colonic anastomotic healing under complicated conditions: A systematic review.

Authors:  Malene Nerstrøm; Peter-Martin Krarup; Lars Nannestad Jorgensen; Magnus S Ågren
Journal:  World J Gastrointest Surg       Date:  2016-05-27

Review 2.  The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.

Authors:  Malvina Hoxha; G Enrico Rovati; Aurora Bueno Cavanillas
Journal:  Eur J Clin Pharmacol       Date:  2017-04-04       Impact factor: 2.953

3.  The protective role of montelukast against intestinal ischemia-reperfusion injury in rats.

Authors:  Shenbao Wu; Xuxing Zhu; Zhonghai Jin; Xiuping Tong; Liqin Zhu; Xiaofei Hong; Xianfei Zhu; Pengfei Liu; Weidong Shen
Journal:  Sci Rep       Date:  2015-10-26       Impact factor: 4.379

4.  Montelukast for Medical Delay in Flap Surgery.

Authors:  Maryam Iranpour; Ali Khodarahmi; Nima Khodarahmi; Mohammad Shafiee; Reza Malekpourafshar; Nozar Nakhaee
Journal:  World J Plast Surg       Date:  2020-01

5.  MOntelukast as a potential CHondroprotective treatment following Anterior cruciate ligament reconstruction (MOCHA Trial): study protocol for a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Cale A Jacobs; Caitlin E W Conley; Virginia Byers Kraus; Drew A Lansdown; Brian C Lau; Xiaojuan Li; Sharmila Majumdar; Kurt P Spindler; Nicole G Lemaster; Austin V Stone
Journal:  Trials       Date:  2022-01-31       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.